Circassia Falls Most Ever as Cat-Allergy Drug Fails in TrialBy
Shares down as much as 67 percent, most since 2014 IPO
Company halts work on grass, ragweed allergy therapies
Circassia Pharmaceuticals Plc, a U.K. drugmaker backed by investor Neil Woodford, plunged by a record 67 percent in London trading after the company’s drug to prevent cat allergies failed to work better than a placebo in a clinical trial.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- One of the World’s Hottest Stocks Is Now Tumbling
- This Rare Bear Who Called the Crash Warns Housing Is Too Hot Again
- Recent ‘Odd’ Market Moves May Be a Warning Sign for Stocks
- The Global Economy Is Doing Just Fine, But the Davos Elite Is Worried
- U.S. Stocks Gain as Senate Votes to End Shutdown: Markets Wrap